Fudan Zhangjiang: The price reduction of Doxorubicin Liposome Injection is not less than 35%.

Jin10 News on April 30, Fudan Zhangjiang announced that the company has decided to adjust the market retail price of Doxorubicin Liposome Injection starting from May 1, 2025, with a price reduction of no less than 35% compared to the previous bidding price. The sales revenue of this drug in 2024 is expected to be approximately 210 million RMB, accounting for 29% of the company's total annual sales revenue. The price adjustment is expected to have an adverse impact on the company's sales revenue for 2025 and the subsequent execution period, potentially leading to a risk of single-product losses for this drug in 2025.

View Original
The content is for reference only, not a solicitation or offer. No investment, tax, or legal advice provided. See Disclaimer for more risks disclosure.
  • Reward
  • 1
  • Share
Comment
0/400
No comments